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Abstract
Background: Hepatocellular carcinoma (HCC) is the fifth most common neoplasia in the world. In the past,
treatment of advanced HCC with conventional antineoplastic drugs did not result in satisfactory outcomes:
recently, in this patient population the oral multikinase inhibitor sorafenib has been able to induce a statistically
significant improvement of overall survival. Similarly to other anti-angiogenic drugs employed in other tumour
types, also sorafenib seldom induces the dimensional tumour shrinking usually observed with conventional
cytotoxic drugs: data gathered from studies carried out with sorafenib and other competitors under development
do not report any complete response in HCV-induced HCC.
Case presentation: An 84-year old man with a long-lasting history of chronic HCV hepatitis was referred to our
Institution for an ultrasonography investigation of a focal hepatic lesion. To better characterize the liver disease and
clearly define the diagnosis of the focal hepatic lesion, the patient was hospitalized in our department. Laboratory
and instrumental investigations confirmed the clinical picture of HCV-related liver cirrhosis and identified a hepatic
lesion of about 6 cm featuring infiltrating HCC with thrombosis of the portal trunk. Due to the advanced stage of
the disease, therapy with sorafenib 400 mg bid was started. Right from one month after the treatment was started,
a reduction of alpha-fetoprotein level was observed which, by the third month, turned down within the normal
limits. In addition the CT scan showed 50% reduction of the neoplastic lesion along with canalization of the portal
trunk. At the sixth month the normalization of the alpha-fetoprotein level at the lower limit of normality was
confirmed and the MRI showed complete disappearance of the neoplasia. In addition a reduction of a metallo-
proteinase serum level was obserdved. At the twelfth month a further MRI confirmed complete response had been
maintained. At present the patient is in a follow-up program to evaluate the duration of the complete response.
Conclusions: This case is worth mentioning since, to the best of our knowledge, it represents the first evidence of
complete response to sorafenib in an elderly patient with advanced HCV-related HCC.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon neoplasia worldwide with an incidence of about
620,000 new cases per year, and represents the third
most common cancer-related cause of death. Even
though it is particularly widespread in Asia and Africa,
an increase of incidence has occurred in the last years
also in the Western countries [1]. Five-year survival
from diagnosis, strictly related to the stage of disease,
has been estimated between 48% and 75% [2-4]. In the
past, the treatment of advanced HCC with conventional
antineoplastic drugs did not result in satisfactory out-
comes [5]. In the recent years, however, advances
achieved in the knowledge of molecular mechanisms
underlying the growth of HCC led to the development
of new entities useful for the treatment of hyper-vascu-
larized tumours such as HCC. In this scenario, the oral
multikinase inhibitor sorafenib is the only drug which is
in two phase III pivotal, placebo-controlled clinical trials
undertaken in patients with advanced HCC in the Wes-
tern countries and in the Asia-Pacific area has been able
to induce a statistically significant improvement of over-
all survival [6-8]. Similarly to other anti-angiogenic
drugs, also sorafenib seldom induces the dimensional
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ing to conventional cytotoxic drugs: data gathered from
studies carried out with sorafenib and other competitors
under development do not report any complete
response in Hepatitis C Virus (HCV)-induced HCC.
Case Presentation
In November 2009, an 84-year old patient was referred to
our unit to ultrasonographically characterize a focal liver
lesion of about 6 cm with thrombosis of the left portal
trunk (PVT). The patient was in good shape (ECOG PS
0) with a history of chronic HCV-related hepatopathy
clinically-functionally compensated. The aetiological
frame carried out in our Unit confirmed the diagnosis
of chronic hepatopathy evolving towards cirrhosis due to
chronic HCV infection. Hepatic synthesis was well
retained without clinical signs of liver impairment
(CHILD A5). The following parameters turned out
altered: AFP level 353 ng/ml (nv <7); CA 19-9 45.8 U/ml
(nv <39); AST 99 (nv <40 U/L), ALT 142 (nv <41 U/l);
platelet count 126/L (nv 150-400). Kidney function was
within the normal limits.
Contrast ultrasonography substantiated the evidence
elsewhere detected. Multidetector abdomen CT scan
(Light Speed Plus, GE Medical Systems, Milwaukee, USA)
carried out using three-phase system following administra-
tion of iodine contrast medium (Iomeron 400, Bracco,
Milan, Italy) confirmed the presence of a lesion of about
6 cm located between the hepatic segments IV and III
characterized by indistinct margins and infiltrating, with
wash-in in arterial phase and wash-out in late phase, typi-
cal of HCC. The lesion spread from the liver dome and
from the margin of the Glisson capsule to the anterior
area of the left portal trunk and its branch to segment III
which were clotted. Splenomegaly (16 cm DL) and gall-
bladder microlithiasis were also pointed out (Figure 1).
No signs of ascitis were observed. Chest CT did not detect
any metastatic lesion.
Upper digestive tract endoscopy did not show signs of
esophageal varix. The cardiac function evaluation (ECG,
echocardiography and clinical) excluded any symptom
of heart failure.
On the basis of this picture, a diagnosis of advanced
HCC was made (BCLC C).
Being impossible to utilize loco-regional therapy, a
treatment with sorafenib tablets with a dose of 400 mg
bid was started.
The outcome of the therapy can be summarized as
follows:
1st assessment (after one month) - decrease of AFP
level to 113 ng/ml and conversion of CA-19-9 to normal
values (34 U/ml).
2nd assessment (after three months) -f u r t h e rd e c r e a s e
of AFP value to 6.6 ng/ml. The three-phase multidetec-
tor CT (Light Speed Plus) with contrast medium high-
lighted a marked dimensional reduction of infiltrating
focality at the segment III-IV (from 6 cm to 3 cm)
(Figure 2). Residual disease was predominantly localized
a tt h es e g m e n tI Vo ft h el i v e ri nt h eu p p e rs i t ea r e ao f
the left portal trunk which, in any case, was re-canalized
as compared to the previous assessment. Also the portal
trunk of the (delete) segment III appeared re-canalized.
No evidence of new focalities and continuous absence of
ascites have been pointed out.
3rd assessment (after six months) - After six months of
treatment with sorafenib the AFP value accounted for
2.3 ng/ml. The MRI (Signa HDx; GE Healthcare,
Milwaukee, WI) with liver-specific contrast medium
(Primovist, Bayer Schering) (figure 3) did not identify at
all the lesion at segment III and IV. The portal trunk
was pervious and no other hypervascular lesions in the
liver parenchyma were seen. The parameters of liver
Figure 1 Baseline CT examination: 1a, arterious phase; 1b, portal phase; 1c, late phase. Between III and IV hepatic segment is possible to
observe the presence of a solid lesion with poorly defined margins and infiltrative nature; the lesion is hyperdense in arterial phase and
hypodense in the portal phase and late, and it invades the left main portal vein which is thrombosed.
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evaluation criteria, the disappearance of all the target
lesions led to classify a complete response.
4rd assessment (after twelve months) -B yt h et w e l f t h
month the patient performed a new MRI with liver-spe-
cific contrast medium (Primovist, Bayer Schering)
(figure 4 and 5). This confirms CR had been maintained.
Treatment with sorafenib continues and a follow-up
program to evaluate the duration of complete response
is in progress.
The safety aspect of the treatment with sorafenib was
acceptable and manageable: the only adverse events
observed consisted of cutaneous rash requiring treat-
ment with urea cream, and mild-moderate asthenia not
negatively interfering with patient’s daily activities.
Lastly the patient has been addressed to a program aim-
ing at correlating the serum levels of metallo-proteinase 9
with the disease course. Analysis available on the third
month, showed a marked reduction of metallo-proteinase
9 level during the treatment with sorafenib. (Figure 6).
Conclusions
The present case deals with a rapid and complete
response, extensively supported by imaging and by the
evaluation of tumour markers, likely occurred in a
patient with advanced HCC (BCLC stage C) treated
with sorafenib.
T h ee f f i c a c yo fs o r a f e n i bin this tumour has already
been demonstrated in two pivotal multicentre phase III
placebo-controlled clinical trials. The first one (SHARP
study), which accrued more than 600 patients with
advanced HCC with cirrhosis (Child Pugh A) not pre-
viously treated with any systemic therapy, for the first
time showed an advantage in terms of overall survival
in patients with advanced HCC. Among patients trea-
ted with sorafenib, however, only seven (2%) were con-
sidered responders according to RECIST criteria and
no complete response was recorded [6]. Similar con-
siderations can be made as far as the second phase III
clinical study carried out in the Asia Pacific Area is
concerned [7].
To our knowledge, the above reported case represents
the first example of complete response observed in an
elderly patient with advanced HCC and concomitant
HCV infection. So far, literature data reported a case of
complete response to sorafenib in a patient with HCC
due to hemochromatosis [9] and a reduction of a lung
metastasis in a transplanted patient with HBV-related
HCC [10]. Even though spontaneous regressions have
been sometimes described in patients with HCC [11,12],
Figure 2 Three-months follow-up with CT: 2a, arterious phase; 2b, portal phase; 2c, late phase. The three months CT scan document an
apparent reduction in the size of lesion, which is associated with partial recanalization of the left portal branch.
Figure 3 Six months follow up with MRI before and after injection of Primovist: 3a, T1-weighted; 3b, T2-weighted; 3c, arterial phase;
3d, portal venous phase; e, hepatobiliary phase. At six months of treatment, the liver injury is no longer recognizable at MRI examination
and the left portal branch is fully recanalized, as with almost complete response to treatment.
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occurred in an elderly patient with infiltrating disease
and portal thrombosis which, as it is well-known, repre-
s e n tt h em a i nn e g a t i v ep r o g n o s t i cf a c t o r sf o rH C C .I n
our experience, the 84-year old patient showed a good
tolerability to treatment and the incidence and severity
of adverse event did not differ from data reported in the
pivotal studies carried out in HCC. Additional informa-
tion supporting the use of sorafenib in elderly patients
can be found in studies evaluating sorafenib in renal
carcinoma [13,14] which indicate that in these patients a
benefit can be achieved as in the younger ones provided
that a careful monitoring of adverse event is done [15]
Another interesting point is the re-canalization of the
portal vein. Portal thrombosis is a serious complication
due to cirrhosis whose frequency increases in patients
with HCC. This event, considered the main negative
prognostic factor in patients with HCC, represents the
final outcome ensuing from the direct invasion of the
portal vein and the production by neoplastic cells of
pro-coagulative cytokines [16]. In our case, a significant
reduction of the infiltrating disease leading to re-canali-
zation of the portal vein has been observed. HCC is a
hypervascular tumor. Literature data reports that the
loss of vascularity indicates tumor necrosis: reduction or
loss of vascularity after therapy might be an important
Figure 4 Twelve-months follow up with MRI before and after after injection of Primovist: 5a, T1-weighted; 5b, T2-weighted:
On baseline T1w.i and T2w.i no sign of changes of signal intensity within the liver parenchyma is appreciable, not even at the level of the
previous lesion of segment III.
Figure 5 Twelve-months follow up with MRI before and after after injection of Primovist: 6a, arterial phase; 6b portal venous phase;
6c portal venous phase delayed; 6d hepatobiliary phase. On post contrastographic dynamic study, there is no focal enhancement on
arterial phase 6a, nor signs of portal branches invasion on portal venous phase 6b, nor areas of hypointensity on delayed phase 6c. On
hepatobiliary phase 6d, homogeneous enhancement of the previous neoplastic parenchyma of segment III is now appreciable.
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been hypothesized that sorafenib could exert a dual
activity: the first one directly on neoplastic cells and the
second one trough a modulation of pro-thrombotic
cytokines [16].
In fact one report has suggested that Vascular
Endothelial Growth Factor (VEGF) may play an impor-
tant role both in HCC angiogenesis, in portal thrombo-
sis and its evolution [18].
Sorafenib could exert a beneficial effect on portal
thrombosis through the inibition of VEGF pathway.
Since a relation between serum levels of metallo-pro-
teinase 9 and pathogenetic mechanism underlying the
HCC genesis has been recently hypotesized [19-22], this
case has been inserted in a program aiming at verifying
such relation.
Metalloproteinase-9 could be involved in neoangio-
genesis processes and in tumour progression [20,23] and
some in vitro studies seem to indicate that sorafenib
could play a role in modulating the Metalloproteinase-9
expression through a down-regulation process [22]. The
clear reduction of marker serum levels observed after
three months of treatment seem to confirm the hypoth-
esis that the reduction of these levels could be related to
a lower angiogenesis, a lower invasiveness and a lower
disease progression.
A limiting aspect of this case could lie in the lack of
biopsy. According to the current guidelines, however, in
presence of nodules larger than 2 cm showing a typical
post-contrast pattern (wash-in in the arterial phase and
wash-out in the late phase) biopsy is not strictly required
for diagnosis of HCC. In our case, the diagnosis was
based on the typical feature of a 6 cm lesion subsequently
substantiated by the consistency of the two imaging find-
ings [24,25]. Certainly a biopsy could have been helpful
to get information on the molecular pattern of the dis-
ease and then on the possible interaction with sorafenib.
This surprising and unexpected outcome raises some
questions and could be a matter of debate. For instance,
it could be assumed that in the tumour cells mutations
or alterations of the genomic profile making them more
sensitive to sorafenib could have occurred. If this
hypothesis is trustworthy, it represents a valid reason to
boost new investigations aiming at studying in depth
further genetic and molecular features to identify more
selected, or even individual, patterns of response.
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